2Ahlgren JD, Chemotherapy of pancratic carcinoma.Cancer,1996,78(3):654.
3O'connell MJ. Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol. 1985, 3(3) : 1032.
4Ishikawa O, Ohigashi H, Sasaki Y,et al.Liver perfusion chemotherapy vis both hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas.Am J Surg, 1994,168(4):361.
5Gastrointestinal tumor study group, phase Ⅱ studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil J Clin Oncol, 1986,4(5):1794 .
6Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil doxorubicin and mitomycin,JAMA, 1985,253(10):2061.
7Plunkett W, Huang P, Xu YZ et al . Gemcitabine: metabolism,mechanisms of action and selfpotentiation. Semi Oncol, 1995,22(4 Suppl 11):3.
8Moore M, A randomized trial of gemcitabine (GEM)versus 5-Fu as first line therapy in advanced pancreatic cancer, Proc Am Soc Clin Oncol, 1995,14(1):199.
9Rothenberg ML. A phase Ⅱ trial of gemcitabine in patients wich 5-Fu-refractory pancreas cancer Ann Oncol,1996,7(4):347.
10Rougier D, De Forni M, Adenis A, et al. Phase Ⅱ study of taxotere in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol, 1994,3(1):200.
